Starling Oncology Inc. (STLN)
NASDAQ: STLNHealthcareMedical Care FacilitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
STLN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $655.32M
- EPS (TTM)
- -$0.28
- Dividend yield
- None
- 52-week range
- 2.32 – 7.13
- Day range
- 6.38 – 6.79
- Volume / Avg
- 949.07K / 1.55M
- Beta
- —
- Shares outstanding
- 101.92M
52-week range
STLN stock today
On Oct 7, STLN ended the session at $6.43, shedding $0.15 (2.28%), versus the S&P 500's 0.22% decline. Shares are 9.8% below their 52-week high of $7.13, set on Sep 18, 2026 and 177.2% above the 52-week low of $2.32, near the top of the past year's range. STLN is up 80.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 68.3%.
Starling Oncology has posted a net loss over the last twelve months (EPS of -$0.28), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Starling Oncology
Company profileStarling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- CEO
- Dr. Daniel Virnich FACHE, M.B.A., M.D.
- Headquarters
- Cerritos, CA
- Employees
- 641
- IPO year
- 2020
- Website
- starlingoncology.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$9.00+39.97%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Starling Oncology peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GMRSGMR Solutions Inc. Class A | 10.09 | -1.08% | $545.08M | vs STLN |
| SRTAStrata Critical Medical Inc. Class A | 4.68 | -1.47% | $414.02M | vs STLN |
| CYHCommunity Health Systems Inc. | 2.72 | -0.73% | $383.55M | vs STLN |
| AUNAAuna SA Class A | 5.05 | -1.37% | $373.98M | vs STLN |
| PIIIP3 Health Partners Inc. Class A | 5.63 | +5.62% | $1.15B | vs STLN |
| WWWW International Inc. | 15.08 | -3.83% | $150.78M | vs STLN |
| AIRSAirSculpt Technologies Inc. | 1.82 | -2.15% | $131.21M | vs STLN |
| USPHU.S. Physical Therapy Inc. | 82.96 | -0.80% | $1.24B | vs STLN |
Indexes, lists and sector
Appears in lists
Starling Oncology stock FAQ
What is Starling Oncology's stock price today?
STLN last traded at $6.43 as of Oct 7, 4:00 PM EDT, down 2.28% on the day. Prices are delayed at least 15 minutes.
Who is Starling Oncology's CEO?
Dr. Daniel Virnich FACHE, M.B.A., M.D. is the chief executive officer of Starling Oncology Inc., which has about 641 employees.
What is the STLN 52-week high?
The 52-week high for STLN is $7.13 and the 52-week low is $2.32. The stock is currently 9.8% below its high.